Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

被引：0

作者：

Shragai, Tamir ^{[1
]}

Magen, Hila ^{[2
]}

Lavi, Noa ^{[3
]}

Gatt, Moshe ^{[4
]}

Trestman, Svetlana ^{[1
]}

Zektser, Miri ^{[5
]}

Ganzel, Chezi ^{[6
]}

Jarchowsky, Osant ^{[7
]}

Berger, Tamar ^{[8
]}

Tadmor, Tamar ^{[9
]}

Leiba, Merav ^{[10
]}

Hertzog-Zarfaty, Katrin ^{[11
]}

Horowitz, Netanel ^{[3
]}

Shapira, Michael ^{[12
]}

Varssano, David ^{[1
]}

Berger, Yoav ^{[2
]}

Frenkel, Shahar ^{[4
]}

Krauthammer, Mark ^{[1
]}

Avivi, Irit ^{[13
,14
]}

Luttwak, Efrat ^{[1
]}

Cohen, Yael ^{[13
,14
]}

机构：

[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[2] Sheba Med Ctr, Ramat Gan, Israel

[3] Rambam Hlth Care Campus, Haifa, Israel

[4] Hadassah Med Ctr, Jerusalem, Israel

[5] Soroka Univ Hosp, Beer Sheva, Israel

[6] Shaare Zedek Med Ctr, Jerusalem, Israel

[7] Meir Med Ctr, Kefar Sava, Israel

[8] Rabin Med Ctr, Petah Tiqwa, Israel

[9] Bnei Zion Med Ctr, Haifa, Israel

[10] Assuta Ashdod Med Ctr, Ashdod, Israel

[11] Shamir Med Ctr, Beer Yaagov, Israel

[12] Assuta Ramat HaChayal Hosp, Tel Aviv, Israel

[13] Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[14] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-114

引用

页码：S98 / S98

页数：1

共 50 条

[31] Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha, Attaya
Bahlis, Nizar
Trudel, Suzanne
Weisel, Katja
Koenecke, Christian
Oriol, Albert
Voorhees, Peter M.
Alonso, Aranzazu A.
Callander, Natalie S.
Mateos, Maria-Victoria
Reddy, Nishitha
Hakim, Shawn
Lamacchia, John
Patel, Nashita
Williams, Danae
Jewell, Roxanne. C.
Zhou, Xiangdong
Gupta, Ira
Opalinska, Joanna
Nooka, Ajay K.
CANCER, 2024, 130 (15) : 2629 - 2641
[32] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Baines, Andrea C.
Ershler, Rachel
Kanapuru, Bindu
Xu, Qing
Shen, Guoxiang
Li, Liang
Ma, Lian
Okusanya, Olanrewaju O.
Simpson, Natalie E.
Nguyen, Wanda
Theoret, Marc R.
Pazdur, Richard
Gormley, Nicole J.
CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
[33] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
Cavo, Michele
Delforge, Michel
Dimopoulos, Meletios
Escalante-Barrigon, Fernando
Hultcrantz, Malin
Kleinman, David
Lee, Hans
Vij, Ravi
Greil, Richard
Melchardt, Thomas
Antonioli, Elisabetta
Schjesvold, Fredrik
Lysen, Anna
Kotowsky, Nirali
Camadoo-O'Byrne, Leena
Bitetti, Jacopo
Mouro, Jorge
D'Estrube, Tim
Fry, Mark
Byrne, Julie
Vossen, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
[34] Pomalidomide-based therapy in Relapsed/Refractory Multiple Myeloma: a real-world single-center experience.
Fucci, Ludovica
Fiori, Luciano
Coppetelli, Ugo
Cimino, Giuseppe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S144 - S145
[35] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Meera Mohan
Jorge Monge
Nishi Shah
Danny Luan
Mark Forsberg
Vineel Bhatlapenumarthi
Metodi Balev
Anannya Patwari
Heloise Cheruvalath
Divaya Bhutani
Sharmilan Thanendrarajan
Binod Dhakal
Maurizio Zangari
Samer Al-Hadidi
Dennis Cooper
Suzanne Lentzsch
Frits van Rhee
Anita D’Souza
Aniko Szabo
Carolina Schinke
Rajshekhar Chakraborty
Blood Cancer Journal, 14
[36] Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Mohan, Meera
Shah, Nishi
Luan, Danny
Monge, Jorge
Forsberg, Mark
Bhatlapenumarthi, Vineel
Balev, Metodi
Patwari, Anannya
Cheruvalath, Heloise
Bhutani, Divaya
Thanendrarajan, Sharmilan
Dhakal, Binod
Zangari, Maurizio
Al Hadidi, Samer
Cooper, Dennis L.
Lentzsch, Suzanne
van Rhee, Frits
D'Souza, Anita
Szabo, Aniko
Schinke, Carolina
Chakraborty, Rajshekhar
BLOOD, 2023, 142
[37] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Mohan, Meera
Monge, Jorge
Shah, Nishi
Luan, Danny
Forsberg, Mark
Bhatlapenumarthi, Vineel
Balev, Metodi
Patwari, Anannya
Cheruvalath, Heloise
Bhutani, Divaya
Thanendrarajan, Sharmilan
Dhakal, Binod
Zangari, Maurizio
Al-Hadidi, Samer
Cooper, Dennis
Lentzsch, Suzanne
van Rhee, Frits
D'Souza, Anita
Szabo, Aniko
Schinke, Carolina
Chakraborty, Rajshekhar
BLOOD CANCER JOURNAL, 2024, 14 (01)
[38] The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Mukhopadhyay, Pralay
Abdullah, Hesham A.
Opalinska, Joanna B.
Paka, Prani
Richards, Eric
Weisel, Katja
Trudel, Suzanne
Mateos, Maria-Victoria
Dimopoulos, Meletios Athanasios
Lonial, Sagar
BLOOD CANCER JOURNAL, 2025, 15 (01):
[39] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
Roussel, Murielle
Texier, Nathalie
Germain, Raphael
Sapra, Sandhya
Paka, Prani
Kerbouche, Naima
Colin, Xavier
Leleu, Xavier
BLOOD, 2022, 140 : 4261 - 4263
[40] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
Melody, Megan
Przybylski, Daniel
Robinson, Adam
Lin, Adam
Gordon, Leo
Adekola, Kehinde
Singhal, Seema
Mehta, Jayesh
Moreira, Jonathan
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211

← 1 2 3 4 5 →